We develop generics with proven therapeutic efficacy and safety of administration

Market analysis and strategic adaptation of the portfolio in accordance with the trends is a priority for Antibiotice as a producer of generic drugs.
Our drugs, developed mainly through on-site research programs, complement the traditional portfolio consisting of drugs intended for treating infections from the following therapeutic classes: cardiovascular, central nervous system, digestive tract, anti-inflammatory, dermatologicals, but also products for prevention and enhancing the quality of life, administered by self-medication. Antibiotice owns both the technology and the know-how whichallow it to collaborate with partners from all over the world in order to develop integrated projects – from research to product registration, from bioequivalence studies to completing the application and registration process with relevant authorities abroad in order to sell on foreign markets.

  • US Food and Drug Administration (FDA) approval for Ampicillin for injection (4 strengths) and Nystatin (API)
  • Eight GMP-certified manufacturing lines

  • Integrated Management System covering Quality, Environment, Occupational Health and Safety